Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: CRISPR OMNI nucleases - Emendo Biotherapeutics

Next Previous
X
Search
Drug Profile

Research programme: CRISPR OMNI nucleases - Emendo Biotherapeutics

Alternative Names: CRISPR/Cas9 - Emendo Biotherapeutics; CRISPR/Cas9 gene editing therapies - Emendo; CRISPR/Cas9 gene therapies - Emendo; OMNI Nuclease - Emendo Biotherapeutics

Latest Information Update: 31 May 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Emendo biotherapeutics
  • Class DNA; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hyperlipoproteinaemia type IIa; Inborn genetic disorders; Neutropenia

Most Recent Events

  • 18 May 2022 Pharmacodynamics data from preclinical trial in neutropenia released by Emendo Biotherapeutics
  • 01 May 2022 Preclinical trials in Hyperlipoproteinaemia type IIa in USA (Parenteral) before May 2022
  • 01 May 2022 Preclinical trials in Inborn genetic disorders in USA before May 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top